CrossrefInfokarte
Efficacy and safety of fezolinetant in the treatment of moderate to severe vasomotor symptoms in women for whom hormone therapy is considered inappropriate
Klinická farmakologie a farmacie · 2025-10-30 · 39 (3) · 174-180
DOI: 10.36290/far.2025.062 ↗Abstract
Kein Abstract verfügbar.
EUVIMED